Announcement • Jun 13

BiomX Announces NYSE American Acceptance of Plan to Regain Compliance

On June 10, 2026, BiomX Inc. (the Company) received a written notice from NYSE Regulation stating that it had accepted the Company's plan to regain compliance with the continued listing standards of the NYSE American LLC (NYSE American). The Company submitted a compliance plan to NYSE American on April 24, 2026. NYSE Regulation accepted the plan and granted the Company a plan period through September 25, 2027 to regain compliance with the applicable continued listing standards. As previously disclosed, on March 25, 2026, the Company received written notice from NYSE Regulation that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the NYSE American LLC Company Guide (the Company Guide), which require a listed company to maintain specified levels of stockholders' equity. The notice was based on the Company's reported stockholders' deficit of USD 1.302 million as of December 31, 2025 and its losses from continuing operations and/or net losses in its five most recent fiscal years then ended. The Company was also not eligible for any exemption from the stockholders' equity requirements under Section 1003(a) of the Company Guide. During the plan period, the Company's common stock will continue to be listed and traded on NYSE American, subject to the Company's compliance with the initiatives and conditions set forth in the compliance plan and continued periodic review by NYSE Regulation. Until the Company regains compliance, a BC (below compliance) indicator will be disseminated with the Company's ticker symbol, and the Company will be included on the NYSE American's list of noncompliant issuers published on the Exchange's website. If the Company does not regain compliance with the applicable continued listing standards by the end of the plan period, or does not make progress consistent with the compliance plan during the plan period, NYSE Regulation may initiate delisting proceedings. The Company is committed to taking the actions set forth in the plan and intends to use all reasonable efforts to regain compliance with the applicable continued listing standards within the plan period. The Company can provide no assurances that it will be able to make progress with respect to its Plan that the NYSE Regulation will determine to be satisfactory, that it will regain compliance with Section 1003(a)(i), (ii) or (iii) of the Company Guide during the Plan Period, or that developments and events occurring subsequent to the Company's formulation of the Plan or its acceptance by NYSE Regulation will not adversely affect the Company's ability to make sufficient progress and/or regain compliance with the aforementioned sections of the Company Guide during the Plan Period or result in the Company's failure to be in compliance with other NYSE American continued listing standards.

BiomX Inc. Stock Price

PHGE Share Price Performance

PHGE Community Narratives

Regulatory Tailwinds And Antimicrobial Resistance Focus Will Support Long Term Phage Therapy Potential

Regulatory Tailwinds And Antimicrobial Resistance Focus Will Support Long Term Phage Therapy Potential

Trending Discussion

Recently Updated Narratives

Regulatory Tailwinds And Antimicrobial Resistance Focus Will Support Long Term Phage Therapy Potential

Snowflake Analysis

BiomX Inc. Key Details

About PHGE

Recent PHGE News & Updates

BiomX Announces NYSE American Acceptance of Plan to Regain Compliance

BiomX Inc., Annual General Meeting, Jun 26, 2026

BiomX Inc. announced delayed 10-Q filing

Recent updates

BiomX Inc. Competitors

Pulmatrix

Cardio Diagnostics Holdings

Bio Green Med Solution

Alpha Compute